Type I interferons in anticancer immunity

Zitvogel, Laurence, Galluzzi, Lorenzo, Kepp, Oliver, Smyth, Mark J., Kroemer, Guido·2015·Nature Reviews Immunology

DOI 10.1038/nri3845

Cited by (1,000)

Items 101–200 of 1,000

P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers
Anna Seelig · 2020 · Frontiers in Oncology
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu · 2020 · Immunity
Epigenetic reprogramming of tumor cell–intrinsic STING function sculpts antigenicity and T cell recognition of melanoma
Falahat, Rana, Berglund, Anders, Putney, Ryan M., Perez-Villarroel, Patricio, Aoyama, Shota, Pilon-Thomas, Shari, Barber, Glen N., Mulé, James J. · 2021 · Proceedings of the National Academy of Sciences
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn, Sudha Rao · 2017 · Molecular Immunology
Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells
Jeonghyun Ahn, Tianli Xia, Ailem Rabasa, Dillon M. Betancourt, Glen N. Barber · 2018 · Cancer Cell
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Ruan F.V. Medrano, Aline Hunger, Samir Andrade Mendonça, José Alexandre Marzagão Barbuto, Bryan Eric Strauss · 2017 · Oncotarget
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo, Kaiko Kunii, Kristy G. Kuplast-Barr, Bin Gui, Alvin Ziying Lu, Jennifer R. Molina, Elena Minissale, Kerren K. Swinger et al. · 2021 · Cancer Cell
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
Heng Yang, Yuting Ma, Guo Chen, Heng Zhou, Takahiro Yamazaki, Christophe Klein, Federico Pietrocola, Erika Vacchelli, Sylvie Souquère, Allan Sauvat et al. · 2016 · OncoImmunology
HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING
Xiaobo Luo, Christopher R. Donnelly, Wang Gong, Blake R. Heath, Yuning Hao, Lorenza A. Donnelly, Toktam Moghbeli, Yee Sun Tan, Xin Lin, Emily Light Bellile et al. · 2019 · Journal of Clinical Investigation
3D microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells
Parlato, Stefania, De Ninno, Adele, Molfetta, Rosa, Toschi, Elena, Salerno, Debora, Mencattini, Arianna, Romagnoli, Giulia, Fragale, Alessandra, Roccazzello, Lorenzo, Buoncervello, Maria et al. · 2017 · Scientific Reports
IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation
Rajendra Karki, Ein Lee, David E. Place, Parimal Samir, Jayadev Mavuluri, Bhesh Raj Sharma, Arjun Balakrishnan, R. K. Subbarao Malireddi, Rechel Geiger, Qifan Zhu et al. · 2018 · Cell
PARP inhibitors: enhancing efficacy through rational combinations
Deepak Bhamidipati, Jaime Ivan Haro-Silerio, Timothy Anthony Yap, Natalie Y.L. Ngoi · 2023 · British Journal of Cancer
Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs
Stephanie Seneff, Greg Nigh, Anthony M. Kyriakopoulos, Peter Andrew McCullough · 2022 · Food and Chemical Toxicology
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
Chunwan Lu, Asif M. Talukder, Natasha M. Savage, Nagendra Singh, Kebin Liu · 2017 · OncoImmunology
Plasmacytoid dendritic cell in immunity and cancer
Dana K. Mitchell, Sreenivasulu Chintala, Mahua Dey · 2018 · Journal of Neuroimmunology
Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti · 2018 · Frontiers in Oncology
Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles
Pere Dosta, Alexander M. Cryer, Michelle Z. Dion, Tsubasa Shiraishi, Steven Langston, David P. P. Lok, Jianing Wang, Sean Harrison, Tiquella Hatten, Michelle L. Ganno et al. · 2023 · Nature Nanotechnology
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers
Claire Vanpouille‐Box, Silvia Chiara Formenti, Sandra Demaria · 2017 · Clinical Cancer Research
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, Lisa, Routy, Bertrand, Desilets, Antoine, Daillère, Romain, Terrisse, Safae, Kroemer, Guido, Zitvogel, Laurence · 2021 · Cancer Discovery
T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy
Yihui Zhai, Jinming Wang, Tianqun Lang, Ying Kong, Rong Rong, Ying Cai, Wei Ran, Fengqin Xiong, Chao Zheng, Yanke Wang et al. · 2021 · Nature Nanotechnology
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
Camilla Salvagno, Metamia Ciampricotti, Sander Tuit, Cheei‐Sing Hau, Antoinette van Weverwijk, Seth B. Coffelt, Kelly Kersten, Kim Vrijland, Kevin Kos, Thomas Ulas et al. · 2019 · Nature Cell Biology
Type I Interferons and Natural Killer Cell Regulation in Cancer
Lena Müller, Petra Aigner, Dagmar Stoiber · 2017 · Frontiers in Immunology
Immunomodulation by anticancer cell cycle inhibitors
Petroni, Giulia, Formenti, Silvia C., Chen-Kiang, Selina, Galluzzi, Lorenzo · 2020 · Nature Reviews Immunology
Targeting cancer‐related inflammation in the era of immunotherapy
Kyohei Nakamura, Mark John Smyth · 2016 · Immunology and Cell Biology
Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer
Fucikova, Jitka, Moserova, Irena, Urbanova, Linda, Bezu, Lucillia, Kepp, Oliver, Cremer, Isabelle, Salek, Cyril, Strnad, Pavel, Kroemer, Guido, Galluzzi, Lorenzo et al. · 2015 · Frontiers in Immunology
Immune suppression and reversal of the suppressive tumor microenvironment
Kanako Shimizu, Tomonori Iyoda, Masahiro Okada, Satoru Yamasaki, Shin‐ichiro Fujii · 2018 · International Immunology
Nanoparticle‐Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
Lutz Nuhn, Stefaan De Koker, Sandra Van Lint, Zifu Zhong, João Portela Catani, Francis Combes, Kim Deswarte, Yupeng Li, Bart N. Lambrecht, Stefan Lienenklaus et al. · 2018 · Advanced Materials
Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway
Yi‐An Chen, Yiling Shen, Hsuan-Yu Hsia, Yee Peng Tiang, Tzu-Ling Sung, Liuh‐Yow Chen · 2017 · Nature Structural & Molecular Biology
TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression
Aurobind Vidyarthi, Nargis Khan, Tapan Agnihotri, Shikha Negi, Deepjyoti Kumar Das, Mohammad Aqdas, Deepyan Chatterjee, Oscar R. Colegio, Manoj Kumar Tewari, Javed Naim Agrewala · 2018 · Frontiers in Immunology
Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity
Jingjing Liang, Huifang Wang, Wenxiu Ding, Jianxiang Huang, Xuefei Zhou, Huiyang Wang, Xue Dong, Guangyao Li, Enguo Chen, Fei Zhou et al. · 2020 · Science Advances
Bystander T cells in cancer immunology and therapy
Stefanie L. Meier, Ansuman T. Satpathy, Daniel K. Wells · 2022 · Nature Cancer
Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy
Jun‐Long Liang, Xiao‐Kang Jin, Shi‐Man Zhang, Qian-Xiao Huang, Ping Ji, Xin-Chen Deng, Wei‐Hai Chen, Wei‐Hai Chen, Xian‐Zheng Zhang · 2023 · 中国科学通报：英文版
Trial watch: Peptide-based vaccines in anticancer therapy
Lucillia Bezu, Oliver Kepp, Giulia Cerrato, Jonathan G. Pol, Jitka Palich Fucikova, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2018 · OncoImmunology
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Carole Achard, Abera Surendran, Marie-Ève Wedge, Guy Ungerechts, John Cameron Bell, Carolina S. Ilkow · 2018 · EBioMedicine
Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine
Yee Sun Tan, Kanokwan Sansanaphongpricha, Yuying Xie, Christopher R. Donnelly, Xiaobo Luo, Blake R. Heath, Xinyi Zhao, Emily Light Bellile, Hongxiang Hu, Hongwei Chen et al. · 2018 · Clinical Cancer Research
Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway
Marco Durante, Silvia Chiara Formenti · 2018 · Frontiers in Oncology
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
Marie de Charette, Aurélien Marabelle, Roch Houot · 2016 · European Journal of Cancer
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin, Jacob M. Ricca, Svetlana Sadekova, Anton Oseledchyk, Ying Yu, Wendy M. Blumenschein, Jerelyn Wong, Mathieu Gigoux, Taha Merghoub, Jedd D. Wolchok · 2018 · Journal of Clinical Investigation
Immunoregulatory roles of versican proteolysis in the myeloma microenvironment
Chelsea L. Hope, Simon J. Foulcer, Justin C. Jagodinsky, Sarah X. Chen, Jeffrey Lee Jensen, Sanjay Patel, Catherine P. Leith, Ioanna G Maroulakou, Natalie S. Callander, Shigeki Miyamoto et al. · 2016 · Blood
Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Annamaria Gullà, Eugenio Morelli, Mehmet Samur, Cirino Botta, Teru Hideshima, Giada Bianchi, Mariateresa Fulciniti, Stefano Malvestiti, RAO H. PRABHALA, Srikanth Talluri et al. · 2021 · Blood Cancer Discovery
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis
Ling-Xian Zhang, Jian Gao, Xiang Long, Pengfei Zhang, Xin Yang, Shu‐Qiang Zhu, Xu Pei, Bai‐Quan Qiu, Shiwei Chen, Feng Lü et al. · 2022 · Molecular Cancer
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
Michelle von Locquenghien, Catalina Rozalén, Toni Celià-Terrassa · 2021 · Journal of Clinical Investigation
Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect
Chao Wang, Zhaoyi Sun, Chenxuan Zhao, Zhewei Zhang, Haoran Wang, Yang Liu, Yunfei Guo, Bingtao Zhang, Lihong Gu, Yue Yu et al. · 2021 · Journal of Controlled Release
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, Anping, Yi, Ming, Qin, Shuang, Chu, Qian, Luo, Suxia, Wu, Kongming · 2019 · Journal of Hematology & Oncology
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Yangfu Jiang, Hongying Zhang, Jiao Wang, Jinzhu Chen, Zeyu Guo, Yongliang Liu, Hui Ming Hua · 2023 · Journal of Hematology & Oncology
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention
Ben Wylie, Christophe Macri, Justine D. Mintern, Jason C. Waithman · 2019 · Cancers
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Oliver Kepp, Aurélien Marabelle, Laurence Zitvogel, Guido Kroemer · 2019 · Nature Reviews Clinical Oncology
Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
Chunwan Lu, John David Klement, Mohammed L. Ibrahim, Wei Lie Xiao, Priscilla S. Redd, Asha Nayak-Kapoor, Gang Zhou, Kebin Liu · 2019 · Journal for ImmunoTherapy of Cancer
Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer
Lei Zhou, Bo Hou, Dangge Wang, Fang Zhen Sun, Rundi Song, Qian Shao, Hao Wang, Haijun Yu, Yaping Li · 2020 · Nano Letters
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
Dmitriy Zamarin, Rikke Holmgaard, Jacob M. Ricca, Tamar Plitt, Peter Palese, Padmanee Sharma, Taha Merghoub, Jedd D. Wolchok, James Patrick Allison · 2017 · Nature Communications
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications
Martina Musella, Gwenola Manic, Ruggero D. Maria, Ilio Vitale, Antonella Sistigu · 2017 · OncoImmunology
Type I and II Interferons in the Anti-Tumor Immune Response
Sarah Elizabeth Fenton, Diana Saleiro, Leonidas C. Platanias · 2021 · Cancers
Type I interferon and cancer
Peter Holíček, Emma Guilbaud, Vanessa Klapp, Iva Truxová, Radek Špíšek, Lorenzo Galluzzi, Jitka Palich Fucikova · 2023 · Immunological Reviews
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
Erez N. Baruch, Frederico O. Gleber‐Netto, Priyadharsini Nagarajan, Xiayu Rao, Shamima Akhter, Tuany Eichwald, Tongxin Xie, Mohammad Balood, Adebayo Adewale, Shorook Na’ara et al. · 2025 · Nature
Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
Shashi Ashok Gujar, Jonathan G. Pol, Guido Kroemer · 2018 · OncoImmunology
The immuno-oncological challenge of COVID-19
Lisa Derosa, Cléa Melenotte, Frank Griscelli, Bertrand Gachot, Aurélien Marabelle, Guido Kroemer, Laurence Zitvogel · 2020 · Nature Cancer
cGAS‐cGAMP‐STING: The three musketeers of cytosolic DNA sensing and signaling
Jianli Tao, Xiang Zhou, Zhengfan Jiang · 2016 · IUBMB Life
Pro-necrotic molecules impact local immunosurveillance in human breast cancer
Gautier Stoll, Yuting Ma, Heng Yang, Oliver Kepp, Laurence Zitvogel, Guido Kroemer · 2017 · OncoImmunology
RIG-I activation is critical for responsiveness to checkpoint blockade
Simon M Heidegger, Alexander Wintges, Florian Stritzke, Sarah Bek, Katja Steiger, Paul-Albert Koenig, Sascha Göttert, Thomas Engleitner, Rupert Öllinger, Tatiana Nedelko et al. · 2019 · Science Immunology
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Aitziber Buqué, Norma Bloy, Fernando Aranda, Francesca Castoldi, Alexander M.M. Eggermont, Isabelle Cremer, Wolf H. Fridman, Jitka Palich Fucikova, Jérôme Galon, Aurélien Marabelle et al. · 2015 · OncoImmunology
The spectrum of sex differences in cancer
Joshua B. Rubin · 2022 · Trends in cancer
Quality by Design for enabling RNA platform production processes
Simon Daniel, Zoltán Kis, Cleo Kontoravdi, Nilay Shah · 2022 · Trends in biotechnology
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
Mateusz Kciuk, Esam Bashir Yahya, Montaha Mohamed Ibrahim Mohamed, Summya Rashid, Muhammad Omer Iqbal, Renata Kontek, Muhanad Abdullah Abdulsamad, Abdulmutalib Alabeed Allaq · 2023 · Cancers
Immunosurveillance in clinical cancer management
Guido Kroemer, Timothy An-thy Chan, Alexander M.M. Eggermont, Lorenzo Galluzzi · 2023 · CA A Cancer Journal for Clinicians
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.
2017 · Cancer Research
Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy
Sunyoung Kim, Sohyun Kim, Jung‐Eun Kim, Sang Nam Lee, Il Woo Shin, Hong Sik Shin, Seung Mo Jin, Young‐Woock Noh, Young Ju Kang, Young Seob Kim et al. · 2019 · ACS Nano
Machete identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis
Barriga, Francisco M., Tsanov, Kaloyan M., Ho, Yu-Jui, Sohail, Noor, Zhang, Amy, Baslan, Timour, Wuest, Alexandra N., Del Priore, Isabella, Meškauskaitė, Brigita, Livshits, Geulah et al. · 2022 · Nature Cancer
From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment
Kellsye P. Fabian, Benjamin Wolfson, James W. Hodge · 2021 · Frontiers in Oncology
Acid‐Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer
Fangmin Chen, Tianliang Li, Huijuan Zhang, Madiha Saeed, Xiaoying Liu, Lujia Huang, Xiyuan Wang, Jing Gao, Bo Hou, Yi Lai et al. · 2022 · Advanced Materials
Type I interferons and dendritic cells in cancer immunotherapy
2019 · International Review of Cell and Molecular Biology
The immune network in thyroid cancer
Maria Rosaria Galdiero, Gilda Varricchi, Gianni Marone · 2016 · OncoImmunology
Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
Anne Huber, Floris F. Dammeijer, Joachim G.J.V. Aerts, Heleen H. Vroman · 2018 · Frontiers in Immunology
Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway
Kevin M. Alicea-Torres, Emilio Sanseviero, Jun Gui, Jinyun Chen, Filippo Veglia, Qiujin Yu, Laxminarasimha Donthireddy, Andrew V. Kossenkov, Cindy Lin, Shuyu Fu et al. · 2021 · Nature Communications
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
Martina Musella, Andrea Guarracino, Nicoletta Manduca, Claudia Galassi, Eliana Ruggiero, Alessia Potenza, Ester Maccafeo, Gwenola Manic, Luca Mattiello, Sara Soliman Abdel Rehim et al. · 2022 · Nature Immunology
Vaccine adjuvants: Tailoring innate recognition to send the right message
Ed C. Lavelle, Craig P. McEntee · 2024 · Immunity
DNA Damage Response and Oxidative Stress in Systemic Autoimmunity
Vassilis L. Souliotis, Nikolaos I. Vlachogiannis, Maria Belen Pappa, Alexandra Argyriou, Panagiotis A. Ntouros, Petros Paul Sfikakis · 2019 · International Journal of Molecular Sciences
New viral vectors for infectious diseases and cancer
Emanuele Sasso, Anna Morena D’Alise, Nicola Zambrano, Elisa Scarselli, Antonella Folgori, Alfredo Nicosia · 2020 · Seminars in Immunology
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo
Rocio Montes De Oca, Alireza Alavi, Nick Vitali, Sabyasachi Bhattacharya, Christina Blackwell, Krupa J. Patel, Laura Seestaller‐Wehr, Heather Kaczynski, Hong Shi, Eric Dobrzynski et al. · 2021 · Molecular Cancer Therapeutics
The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma
Shufang Jin, Mingyu Kenneth Li, Hanyue Chang, Ruijie Wang, Zhiyuan Zhang, Jianjun Zhang, Yue He, Hailong Ma · 2022 · Molecular Cancer
Advances and perspectives of PARP inhibitors
Yi, Ming, Dong, Bing, Qin, Shuang, Chu, Qian, Wu, Kongming, Luo, Suxia · 2019 · Experimental Hematology & Oncology
Negative regulation of type I IFN signaling
Arimoto, Kei-Ichiro, Miyauchi, Sayuri, Stoner, Samuel A, Fan, Jun-Bao, Zhang, Dong-Er · 2018 · Journal of Leukocyte Biology
Versican-Derived Matrikines Regulate Batf3–Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer
Chelsea L. Hope, Philip B. Emmerich, Athanasios Papadas, Adam C. Pagenkopf, Kristina A. Matkowskyj, Dana R. Van De Hey, Susan N. Payne, Linda J. Clipson, Natalie S. Callander, Peiman Hematti et al. · 2017 · The Journal of Immunology
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
Carine El Sissy, Amos Kirilovsky, Marc Van den Eynde, Ana-Maria Mușină, Maria-Gabriela Aniței, Alfredo Romero, Florence Marliot, Audelaure Junca, J. Doyen, Bernhard Mlecnik et al. · 2020 · Clinical Cancer Research
The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING–IFN-β pathway
Mariko Takahashi, Chan‐Wang Jerry Lio, Anaamika Campeau, Martin Steger, Ferhat Ay, Matthias Mann, David J. Gonzalez, Mohit Jain, Sonia Sharma · 2021 · Nature Immunology
Turning tumors from cold to inflamed to improve immunotherapy response
Camille Lea Gerard, Julie Delyon, Alexandre M. Wicky, Krisztián Homicskó, Michel A. Cuendet, Olivier Alain Michielin · 2021 · Cancer Treatment Reviews
Trial Watch—Oncolytic viruses and cancer therapy
Jonathan G. Pol, Aitziber Buqué, Fernando Aranda, Norma Bloy, Isabelle Cremer, Alexander M.M. Eggermont, Philippe Erbs, Jitka Palich Fucikova, Jérôme Galon, Jean‐Marc Limacher et al. · 2015 · OncoImmunology
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, Giorgio, Wu, Qi, Le Naour, Julie, Vacchelli, Erika, Galluzzi, Lorenzo, Kroemer, Guido, Kepp, Oliver · 2020 · OncoImmunology
Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression
Katlinskaya, Yuliya V., Katlinski, Kanstantsin V., Yu, Qiujing, Ortiz, Angelica, Beiting, Daniel P., Brice, Angela, Davar, Diwakar, Sanders, Cindy, Kirkwood, John M., Rui, Hallgeir et al. · 2016 · Cell Reports
cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
Guohao Li, Xiangqian Zhao, Zuda Zheng, Hucheng Zhang, Yundi Wu, Yangkun Shen, Qi Chen · 2024 · Cellular and Molecular Life Sciences
Clinical approaches to overcome PARP inhibitor resistance
Yutian Zou, Hanqi Zhang, Pangzhou Chen, Jiayi Tang, Siwei Yang, Christophe Nicot, Ziyun Guan, Xing Li, Hailin Tang · 2025 · Molecular Cancer
Genetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine
Patrícia Kauanna Fonseca Damasceno, Thaís Alves de Santana, Girlaine Café Santos, Iasmim Diniz Orge, Daniela Nascimento Silva, Juliana Fonseca Albuquerque, Giulia Golinelli, Giulia Grisendi, Massimo Pinelli, Ricardo Ribeiro dos Santos et al. · 2020 · Frontiers in Cell and Developmental Biology
Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials
Bin Li, Juan Jin, Duancheng Guo, Zhonghua Tao, Xichun Hu · 2023 · Cancers
STAT3/p53 pathway activation disrupts IFN-β–induced dormancy in tumor-repopulating cells
Yuying Liu, Jiadi Lv, Jinyan Liu, Xiaoyu Liang, Xun Jin, Jing Xie, Le Zhang, Degao Chen, Roland Fiskesund, Ke Tang et al. · 2018 · Journal of Clinical Investigation
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Nolwenn Lucas, Matthieu Duchmann, Philippe Rameau, Floriane Noël, Paula Michea, Véronique Saada, Olivier Kosmider, Gérard Pierron, Martín E. Fernández-Zapico, Matthew T. Howard et al. · 2019 · Leukemia
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors
Lulu Wang, Lin Yang, Chen Wang, Zhao Wei, Zhenlin Ju, Wei Zhang, Jianfeng Shen, Yang Peng, Clemens An, Yen T. Luu et al. · 2020 · Journal of Clinical Investigation
Tumor-suppressor function of Beclin 1 in breast cancer cells requires E-cadherin
Tobias Wijshake, Zhongju Zou, Beibei Chen, Lin Zhong, Guanghua Xiao, Yang Xie, John G. Doench, Lynda B. Bennett, Beth Levine · 2021 · Proceedings of the National Academy of Sciences
Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a–LCOR axis
Toni Celià-Terrassa, Daniel Dan Liu, Abrar Choudhury, Xiang Hang, Yong Wei, Jose Zamalloa, Raymundo Alfaro‐Aco, Rumela Chakrabarti, Yi‐Zhou Jiang, Bong Ihn Koh et al. · 2017 · Nature Cell Biology
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Gilda Varricchi, Stefania Loffredo, Giancarlo Marone, Luca Modestino, Poupak Fallahi, Silvia Martina Ferrari, Amato de Paulis, Alessandro Antonelli, Maria Rosaria Galdiero · 2019 · International Journal of Molecular Sciences
Immunotherapy: an alternative promising therapeutic approach against cancers
Sneh Lata Gupta, Srijani Basu, Vijay Soni, Rishi Kumar Jaiswal · 2022 · Molecular Biology Reports
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies
Jacob P. van Vloten, Samuel Tekeste Workenhe, Sarah K. Wootton, Karen Louise Mossman, Byram W. Bridle · 2018 · The Journal of Immunology